Assessing the potential impact of non-proprietary drug copies on quality of medicine and treatment in patients with relapsing multiple sclerosis: the experience with fingolimod.
about
Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimodUse of Fingolimod in the Management of Relapsing-Remitting Multiple Sclerosis: Experience from Latin AmericaDetermination of elemental impurities in pharmaceutical products and related matrices by ICP-based methods: a review.
P2860
Assessing the potential impact of non-proprietary drug copies on quality of medicine and treatment in patients with relapsing multiple sclerosis: the experience with fingolimod.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Assessing the potential impact ...... he experience with fingolimod.
@ast
Assessing the potential impact ...... he experience with fingolimod.
@en
type
label
Assessing the potential impact ...... he experience with fingolimod.
@ast
Assessing the potential impact ...... he experience with fingolimod.
@en
prefLabel
Assessing the potential impact ...... he experience with fingolimod.
@ast
Assessing the potential impact ...... he experience with fingolimod.
@en
P2093
P2860
P356
P1476
Assessing the potential impact ...... he experience with fingolimod.
@en
P2093
Imre Bajusz
Jorge Correale
Nadina Frider
Snezana Milojevic
P2860
P304
P356
10.2147/DDDT.S66398
P407
P577
2014-06-25T00:00:00Z